| Sector |
Healthcare
|
Compare with Sector peers |
| Industry |
Medical Equipment/Supplies/Accessories
|
Compare with Industry peers |
| Website | http://www.nureca.com | |
| Market Cap | 1,082.62 Cr. | |
| Enterprise Value(EV) | 964.56 Cr. | 2021-09 |
| Financial Indicators | ||
|---|---|---|
| Earnings per share (EPS) | 50.25 | Trailing Twelve Months Ending 2021-12 |
| Price-Earning Ratio (PE) | 21.54 | Trailing Twelve Months Ending 2021-12 |
| Industry PE | 39.51 | Trailing Twelve Months Ending 2021-12 |
| Book Value / Share | 207.47 | Trailing Twelve Months Ending 2021-12 |
| Price to Book Value | 5.22 | Calculated using Price: 1,082.60 |
| Dividend Yield | 0.18 | Period Ending 2021-03 |
| No. of Shares Subscribed | 1.00 Cr. | 10,000,175 Shares |
| FaceValue | 10 | |
| Company Profile | ||
|
Nureca is a B2C company engaged in the business of home healthcare and wellness products, which offers quality, durability, functionality, usability and innovative designs. It enables its customers with tools to help them monitor chronic ailments and other diseases, to improve their lifestyle. It is a digital first company wherein it sells its products through online channel partners such as e-commerce players, distributors and retailer. Further, it also sells its products through its own website drtrust.in. The company has most of the product lines supporting home health market in India, making it a one-stop solution provider. Dr Trust is a known for its innovative products in the market, and, with the segment showing significant potential for growth, the company is positioned to show significant growth. The company has a diversified product portfolio, which primarily caters to home healthcare sector. It provides an improved product mix to its customers and their preferences thereby targeting a wider customer base. Its growth is further driven by its ability to make available an assortment of quality products under trusted brands built by the company. Products: Currently, the company classify its products portfolio under the following five categories such as:
Key awards, recognitions and accreditations
Major events and milestones:
|
||
Company Profile
Nureca is a B2C company engaged in the business of home healthcare and wellness products, which offers quality, durability, functionality, usability and innovative designs. It enables its customers with tools to help them monitor chronic ailments and other diseases, to improve their lifestyle. It is a digital first company wherein it sells its products through online channel partners such as e-commerce players, distributors and retailer. Further, it also sells its products through its own website drtrust.in.
The company has most of the product lines supporting home health market in India, making it a one-stop solution provider. Dr Trust is a known for its innovative products in the market, and, with the segment showing significant potential for growth, the company is positioned to show significant growth.
The company has a diversified product portfolio, which primarily caters to home healthcare sector. It provides an improved product mix to its customers and their preferences thereby targeting a wider customer base. Its growth is further driven by its ability to make available an assortment of quality products under trusted brands built by the company.
Products:
Currently, the company classify its products portfolio under the following five categories such as:
Key awards, recognitions and accreditations
Major events and milestones:
| 1 Day |
|
-3.21% |
| 1 Week |
|
+2.35% |
| 1 Month |
|
-21.49% |
| 3 Month |
|
-16.77% |
| 6 Month |
|
-27.65% |
| 1 Year |
|
-33.11% |
| 2 Year |
|
|
| 5 Year |
|
|
| 10 Year |
|
| 4 years | 2018-03 | 2019-03 | 2020-03 | 2021-03 | |
| Return on Equity (%) | 426.30 | 162.03 | 61.23 | 52.39 | |
| Return on Capital Employed (%) | 255.06 | 179.97 | 56.70 | 66.70 | |
| Return on Assets (%) | 44.35 | 40.78 | 22.30 | 39.61 |
| Particulars | 5 years | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2021-09* Rs. Cr. |
| Shh. Funds | 2 | 8 | 15 | 163 | 203 | |
| Non Curr. Liab. | 0 | 0 | 9 | 3 | 3 | |
| Curr. Liab. | 5 | 15 | 10 | 34 | 27 | |
| Minority Int. | ||||||
| Equity & Liab. | 7 | 24 | 34 | 200 | 233 | |
| Non Curr. Assets | 0 | 1 | 1 | 4 | 15 | |
| Curr. Assets | 7 | 23 | 33 | 196 | 218 | |
| Misc. Exp. not W/O | ||||||
| Total Assets | 7 | 24 | 34 | 200 | 233 |
| Particulars | 5 years | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2021-12 Rs. Cr. TTM |
| Net Sales | 20 | 62 | 99 | 213 | 246 | |
| Other Income | 0 | 0 | 0 | 3 | 7 | |
| Total Income | 20 | 62 | 99 | 216 | 254 | |
| Total Expenditure | -16 | -53 | -90 | -152 | -184 | |
| PBIDT | 4 | 9 | 10 | 64 | 70 | |
| Interest | 0 | 0 | -1 | -2 | -1 | |
| Depreciation | 0 | 0 | 0 | 0 | -1 | |
| Taxation | -1 | -3 | -2 | -16 | -18 | |
| Exceptional Items | ||||||
| PAT | 3 | 6 | 6 | 46 | 50 | |
| Minority Interest | ||||||
| Share Associate | ||||||
| Other Related Items | ||||||
| Consolidated Net Profit | 3 | 6 | 6 | 46 | 50 | |
| Adjusted EPS | 445 | 889 | 914 | 46 | 50 |
| Particulars | 4 years | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. |
| Cash Fr. Operatn. | 0 | 0 | -8 | 35 | |
| Cash Fr. Inv. | 0 | 0 | 0 | -110 | |
| Cash Fr. Finan. | 0 | 0 | 8 | 92 | |
| Net Change | 0 | 0 | 0 | 17 | |
| Cash & Cash Eqvt | 0 | 0 | 0 | 17 |
|
Fri, 20 May 2022
Board Meeting Intimation for Notice Of Board Meeting Nureca Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 28/05/2022 inter alia to consider and approve inter-alia the audited Financial Results (Standalone and Consolidated) for the fourth quarter and full year ended on March 31 2022. |
|||||||||||||||||||||
|
Fri, 29 Apr 2022
Compliances-Reg.24(A)-Annual Secretarial Compliance Secretarial Compliance Report for the year ended March 31 2022 |
|||||||||||||||||||||
|
Tue, 26 Apr 2022
Format of Initial Disclosure to be made by an entity identified as a Large Corporate Format of Initial Disclosure to be made by an entity identified as a Large Corporate.
We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26 2018. No Name of the Company Secretary: CHETNA ANAND Designation: COMPANY SECRETARY AND COMPLIANCE OFFICER EmailId: CHETNA.ANAND@NURECA.COM Name of the Chief Financial Officer: NISHANT GARG Designation: CHIEF FINANCIAL OFFICER EmailId: NISHANT.GARG@NURECA.COM Date: 26/04/2022 Note: In terms para of 3.2(ii) of the circular beginning F.Y 2022 in the event of shortfall in the mandatory borrowing through debt securities a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore an entity identified as LC shall provide in its initial disclosure for a financial year the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets. |
| Tue, 24 May 2022 |
Closing Below Previous Low
|
Close Within 52 Week Low Zone
|
Close Entering 52 Week Low Zone
|
High Decrease 1 Month
|
High Decrease 3 Months
|
Equities
M.F.
Sectors